



Attendee Welcome Packet |

January 25–29, 2026
Viewline Resort Snowmass
Snowmass, Colorado



AMERICAN COLLEGE
of RHEUMATOLOGY
Empowering Rheumatology Professionals

Table of Contents

WRS Agenda		<u>3</u>
Wi-Fi, Lift Information		<u>5</u>
CE/MOC Information		<u>6</u>
WRS Credit Tracker		<u>8</u>
Meeting Map		<u>9</u>
Exhibit Hall Map		<u>10</u>
Acknowledgements		<u>14</u>
Industry Acknowledgements		<u>15</u>

Schedule is subject to change. All times are in Mountain Time.

SATURDAY, JANUARY 24		
Dinner with Amgen–Industry Supported Symposia (No CE Provided) Achieving and Sustaining Remission in Severe Active ANCA-Associated Vasculitis: GPA and MPA <i>Presented by Dr. Adam Kilian, Sponsored by Amgen</i> 6:00 PM Registration, 6:30–7:30 PM Program		
SUNDAY, JANUARY 25		
7:00–8:00 AM	Guideline-Informed Treatment of Lupus	Sheetal Desai, MD
8:00–9:00 AM	Skin Manifestations of Lupus and Dermatomyositis: Implications for Treatment	Victoria Werth, MD
4:30–5:30 PM	Update on Antiphospholipid Antibody Syndrome	Sheetal Desai, MD
5:30–6:30 PM	Medical Challenges Met with Art, Sculpture, and Song	James Louie, MD, MACR
<i>Opening Reception starts at 6:35pm in the Exhibit Hall</i>		
MONDAY, JANUARY 26		
7:00–8:00 AM	Vasculitis: The Other Ones	Peter Merkel, MD, MPH
8:00–9:00 AM	Panel on Lupus	Sheetal Desai, MD Victoria Werth, MD
4:30–5:30 PM	Lung Manifestations of Vasculitis	Ulrich Specks, MD
5:30–6:30 PM	Sports Medicine for the Rheumatologist	Carlin Senter, MD
TUESDAY, JANUARY 27		
7:00–8:00 AM	Update on Musculoskeletal Ultrasound	Dana DiRenzo, MD
8:00–9:00 AM	Rhomboids and Rods: New Insights into CPPD	John FitzGerald, MD, PhD, RhMSUS
4:30–5:30 PM	Novel Approaches to Sjögren's Disease	Dana DiRenzo, MD
5:30–6:30 PM	Points on Joints	Moderator: Silvia Ross, MD

continued

Dinner With Novartis–Industry Supported Symposia (No CE Provided) Reframing Sjögren's Disease: Not a Syndrome but a Systemic Autoimmune Disease That Can Be Serious and Progressive <i>Presented by Dr. Dana DiRenzo, Sponsored by Novartis Pharmaceutical Corporation</i> 6:30 PM Registration, 7:00–8:00 PM Program		
WEDNESDAY, JANUARY 28		
7:00–8:00 AM	Rheumatoid Arthritis in 2026	Michael Weinblatt, MD
8:00–9:00 AM	New Thinking About Axial Spondyloarthritis	Chris Ritchlin, MD, MPH
4:30–5:30 PM	Raynaud's Phenomenon and Critical Digital Ischemia	Francesco Boin, MD
5:30–6:30 PM	Panel on Inflammatory Arthritis	Michael Weinblatt, MD Jeff Curtis, MD, MS, MPH Chris Ritchlin, MD, MPH
THURSDAY, JANUARY 29		
7:00–8:00 AM	Advances in the Management of Idiopathic Inflammatory Myositis	Julie Paik, MD, MHS
8:00–9:00 AM	Artificial Intelligence and Rheumatology	Jeff Curtis, MD, MS, MPH
4:30–5:30 PM	Myositis Mimics	Julie Paik, MD, MHS
5:30–6:30 PM	Intersection Between Metabolic and Immune Syndromes	John FitzGerald, MD, PhD, RhMSUS

Agenda: [Winter Rheumatology Symposium 2026 Program Schedule](#)

Wi-Fi Login Information

Network Name: **WRS26**

Password: **ACRWRS2026**

Address

100 Elbert Ln, Snowmass Village, CO 81615

Registration

Visit Registration to pick up your name badge and materials. The registration table will be open each day from 6:00–9:00 AM and 4:00–6:00 PM in the foyer near Salon A.

Meals will be in Salon A-B

Coffee breaks will be in Salon C-E

Lift Information

■ **Viewline Resort Guests:** If you are staying at the Viewline Resort Snowmass, you may collect your reserved lift tickets at the hotel registration desk during check-in through January 25.

■ **All Other Attendees:** Reserved tickets will be available at the WRS Registration Desk from 9:00 AM–10:00 AM, Sunday (Jan 25) through Thursday (Jan 29).

Parking

The Daily Self-Parking Fee is not included in the Resort Fee. Guests who choose to self-park will incur a \$30 per day charge, and Valet Parking for \$55 per day.

Meeting Materials

Syllabi

Program syllabi will be posted online and can be accessed via the WRS meeting page by logging in to the ACR Education Center.

Session Slides and Handouts

You may also access the PowerPoint slides from the presentations and PDF handout content on demand via the ACR Education Center.

How to Access the WRS Meeting Page in the ACR Education Center

Login Instructions

1. Log in to the [ACR Education Center](https://learn.rheumatology.org) [learn.rheumatology.org]
2. On the main navigation menu, click **My Education**.
3. Select **My Learning** to see your learning information.
4. Scroll to the **My Meetings** section.
5. Click on **Winter Rheumatology Symposium 2026** to enter the meeting page.

If you have questions, watch this [demonstration video](#), visit the [Help Center](#), or contact education@rheumatology.org.

Note: Access to content will be made available to attendees on Sunday, January 25

The Winter Rheumatology Symposium 2026 is a CE-accredited activity, and it is essential to complete specific steps to earn your CE credits and/or participation certificate. Please review the instructions below carefully to ensure you meet all requirements.

Step 1: Complete the Pre-Test Before the Activity

■ Accessing the Pre-Test:

- ❑ Log in to the [ACR Education Center](https://learn.rheumatology.org) at learn.rheumatology.org.
- ❑ Once logged in, navigate to the **My Learning** page.
- ❑ In the **My Meetings** section, locate and click on **ACR Winter Rheumatology Symposium 2026**.
- ❑ Find and click the **Pre-Test** link to complete the assessment.

Note: *The pre-test must be completed prior to attending the symposium. The pre-test will be available until the end of the first day of the meeting.*

CE/MOC Information

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CE activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CE activity.

The Winter Rheumatology Symposium 2026 is approved by the American College of Rheumatology to provide Continuing Medical Education [CME] and Maintenance of Certification [MOC] credits. This activity is specifically designed for physicians and healthcare professionals. Please keep in mind that, since this activity was not developed through an interprofessional approach, the only credits available are CME and MOC. Be sure to check whether these credits meet your individual credentialing requirements before participating.

CE

Accreditation Statement

In support of improving patient care, the American College of Rheumatology is jointly accredited by the Accreditation Council for Continuing Medical Education [ACCME], the Accreditation Council for Pharmacy Education [ACPE], and

the American Nurses Credentialing Center [ANCC], to provide continuing education for the healthcare team. Provider Number: 0003797

Designation Statement

The American College of Rheumatology designates this Live Activity for a maximum of 20.00 AMA PRA Category 1 Credit[s][™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

See the ACR's [CE Mission Statement](#). For more information, download the [AMA PRA Booklet](#).

CE credit must be claimed by March 30, 2026, at 11:59 PM ET.

MOC

MOC Recognition Statement

Successful completion of this CE activity, which includes participation in the evaluation component, enables the participant to earn up to 20.00 MOC points in the American Board of Internal Medicine's [ABIM] Maintenance of Certification [MOC] program. It is the CE activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.

After submitting a reflective statement with key takeaways from the meeting, MOC points will be applied for ABIM diplomates to the ABIM diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the ABIM Physician Portal. Please allow at least 48 hours for points to display in the portal.

MOC points must be claimed by March 30, 2026, at 11:59 PM ET.

Industry sessions during meals are not eligible for CE/MOC credit claiming.

Financial Disclosures for all faculty are available on the [Winter Rheumatology Symposium webpage](#)

How to Claim Credit Upon Completion of the Activity

Note: Learners can claim credit for an activity once. You will not be able to add credit after claiming.

1. Go to the [ACR Education Center](#) and log in.
2. On the main navigation menu, click **My Education**, then select **My Learning**.
3. Scroll to the **My Meetings** section.
4. Select the **Winter Rheumatology Symposium 2026** to enter the meeting page.
5. After the meeting, complete the post-test (a score of 70% or higher is required to claim credit) and reflective statement (see [Tips for Writing a Reflective Statement](#)).
6. Complete the steps to claim credit and specify the type of credit you will claim.
7. [to claim MOC] Enter or verify your ABIM Diplomate Number /ABP Diplomate Number and date of birth.*
8. After claiming credit, you can access and print a certificate on the activity page in the Certificates section.

*MOC points are sent nightly to ACCME and transferred from there to the respective ABIM/ABP physician portal. Please allow at least 48 hours for points to be reflected in the portal

Additionally, a follow-up 45-day post-test evaluation will be sent to you via email. Your feedback is invaluable to us and plays a crucial role in enhancing our future educational offerings. We encourage your participation in this important process.

The deadline to claim CE credit and MOC points for the Winter Rheumatology Symposium 2026 is March 30, 2026, at 11:59 PM ET.

Questions?

Email education@rheumatology.org.

All times are in Mountain Time.

Schedule is subject to change.

Name:

Use the form below to track your credits. This form is for your own records and by completing this form, you are not claiming credit. To claim credit and print your official certificate, go to [My Credit](#) page.

Session Time	Session Name	CME Credits	
SUNDAY, JANUARY 25			
7:00–8:00 AM	Guideline-Informed Treatment of Lupus	1.00	
8:00–9:00 AM	Skin Manifestations of Lupus and Dermatomyositis: Implications for Treatment	1.00	
4:30– 5:30 PM	Update on Antiphospholipid Antibody Syndrome	1.00	
5:30–6:30 PM	[Humanism] Medical Challenges Met with Art, Sculpture, and Song	1.00	
MONDAY, JANUARY 26			
7:00–8:00 AM	Vasculitis: The Other Ones	1.00	
8:00–9:00 AM	Panel on Lupus	1.00	
4:30– 5:30 PM	Lung Manifestations of Vasculitis	1.00	
5:30–6:30 PM	Sports Medicine for the Rheumatologist	1.00	
TUESDAY, JANUARY 27			
7:00–8:00 AM	Update on Musculoskeletal Ultrasound	1.00	
8:00–9:00 AM	Rhomboids and Rods: New Insights into CPPD	1.00	
4:30– 5:30 PM	Novel Approaches to Sjogren's Disease	1.00	
5:30–6:30 PM	Points on Joints	1.00	
WEDNESDAY, JANUARY 28			
7:00–8:00 AM	Rheumatoid Arthritis in 2026	1.00	
8:00–9:00 AM	New Thinking About Axial Spondyloarthritis	1.00	
4:30– 5:30 PM	Raynaud's Phenomenon and Critical Digital Ischemia	1.00	
5:30–6:30 PM	Panel on Inflammatory Arthritis	1.00	
THURSDAY, JANUARY 29			
7:00–8:00 AM	Advances in the Management of Idiopathic Inflammatory Myositis	1.00	
8:00–9:00 AM	Artificial Intelligence and Rheumatology	1.00	
4:30– 5:30 PM	Myositis Mimics	1.00	
5:30–6:30 PM	Intersection Between Metabolic and Immune Syndromes	1.00	

Meeting Map and Key Locations





Exhibit Hall Map



1. Inmedix, Inc.
2. Novartis-SjD
3. AstraZeneca
4. HouseRX
5. Boehringer Ingelheim
6. Privant
7. Lilly
8. Artiva Biotherapeutics
9. Johnson & Johnson
10. Mallinckrodt
11. Biogen
12. Glaxo Smith Kline

14. Sanofi
15. AbbVie
16. Alexion Rare Disease
17. Novartis-Cosentyx
18. Bristol Myers Squibb (Commercial)
19. Sobi
20. Novartis-Illaris
21. Bristol Myers Squibb (Medical)
22. UCB
23. Amgen-KRYSTEXXA
24. Amgen Uplizna
25. Amgen Tavenos

YOU ARE CORDIALLY INVITED TO ATTEND
A PRESENTATION TITLED:

Achieving and Sustaining Remission in Severe Active ANCA-Associated Vasculitis: GPA and MPA

SPECIFIC TOPICS INCLUDE:

- Heterogeneous and multi-systemic presentation of severe active GPA and MPA
- Pathophysiologic pathways that can serve as targets for therapeutic intervention
- Results from the pivotal ADVOCATE study
- Identification of appropriate patients for TAVNEOS®

PRESENTED BY:

Adam Kilian, MD, FACP, FACP

Director, Rheumatology Fellowship Program
Saint Louis University School of Medicine
St. Louis, MO



Speaker Bio: Dr. Kilian is an Associate Professor of Medicine and the Director of the Rheumatology Fellowship Program at St. Louis University. He is also an active member of the American College of Rheumatology where he serves on several national committees

DATE:

Saturday, January 24th 6:30 PM

Registration Opens 6:00 PM

LOCATION:

Salon A-B, Viewline Hotel
100 Elbert Ln
Snowmass Village, CO 81615

PLEASE RSVP TO:

Sarah James
sjames08@amgen.com
303-968-4722

INDICATION

TAVNEOS (avacopan) is indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Serious hypersensitivity to avacopan or to any of the excipients.

Please see additional Important Safety Information continued on the following page.



IMPORTANT SAFETY INFORMATION (CONT'D)

WARNINGS AND PRECAUTIONS

Hepatotoxicity: Serious cases of hepatic injury have been observed in patients taking TAVNEOS, including life-threatening events. Obtain liver test panel before initiating TAVNEOS, every 4 weeks after start of therapy for 6 months and as clinically indicated thereafter. Monitor patients closely for hepatic adverse reactions, and consider pausing or discontinuing treatment as clinically indicated (refer to section 5.1 of the Prescribing Information). TAVNEOS is not recommended for patients with active, untreated, and/or uncontrolled chronic liver disease (e.g., chronic active hepatitis B, untreated hepatitis C, uncontrolled autoimmune hepatitis) and cirrhosis. Consider the risks and benefits before administering this drug to a patient with liver disease.

Serious Hypersensitivity Reactions: Cases of angioedema occurred in a clinical trial, including 1 serious event requiring hospitalization. Discontinue immediately if angioedema occurs and manage accordingly. TAVNEOS must not be readministered unless another cause has been established.

Hepatitis B Virus (HBV) Reactivation: Hepatitis B reactivation, including life-threatening hepatitis B, was observed in the clinical program. Screen patients for HBV. For patients with evidence of prior infection, consult with physicians with expertise in HBV and monitor during TAVNEOS therapy and for 6 months following. If patients develop HBV reactivation, immediately discontinue TAVNEOS and concomitant therapies associated with HBV reactivation, and consult with experts before resuming.

Serious Infections: Serious infections, including fatal infections, have been reported in patients receiving TAVNEOS. The most common serious infections reported

in the TAVNEOS group were pneumonia and urinary tract infections. Avoid use of TAVNEOS in patients with active, serious infection, including localized infections. Consider the risks and benefits before initiating TAVNEOS in patients with chronic infection, at increased risk of infection, or who have been to places where certain infections are common.

ADVERSE REACTIONS

The most common adverse reactions ($\geq 5\%$ of patients and higher in the TAVNEOS group vs. prednisone group) were nausea, headache, hypertension, diarrhea, vomiting, rash, fatigue, upper abdominal pain, dizziness, blood creatinine increased, and paresthesia.

DRUG INTERACTIONS

Avoid co-administration of TAVNEOS with strong and moderate CYP3A4 enzyme inducers. Reduce TAVNEOS dose when co-administered with strong CYP3A4 enzyme inhibitors to 30 mg once daily. Consider dose reduction of CYP3A4 substrates when co-administering TAVNEOS. Co-administration of avacopan and 40 mg simvastatin increases the systemic exposure of simvastatin. While taking TAVNEOS, limit simvastatin dosage to 10 mg daily (or 20 mg daily for patients who have previously tolerated simvastatin 80 mg daily for at least one year without evidence of muscle toxicity). Consult the concomitant CYP3A4 substrate product information when considering administration of such products together with TAVNEOS.

TAVNEOS is available as a 10 mg capsule.

Please see [Full Prescribing Information and Medication Guide for TAVNEOS](#).

To report a suspected adverse event, call 1-833-828-6367. You may report to the FDA directly by visiting www.fda.gov/medwatch or calling 1-800-332-1088.

PhRMA guidance: Effective January 1, 2022, the PhRMA Code was revised to include certain new requirements for industry provided Speaker Programs. To comply with these new requirements, Amgen will no longer pay for or provide alcohol in connection with our Speaker Programs.

Amgen's COVID-19 speaker program risk mitigation guidance: To mitigate the risk of COVID-19 transmission and in accordance with CDC guidance, attendees are asked to follow the local social distance and safety guidance at all times. Individuals exhibiting signs and symptoms of COVID-19 infection should not attend.

Notice: This event is conducted in accordance with the PhRMA Code on Interaction with Healthcare Professionals and is limited to invited healthcare professionals. Attendance by guests or spouse is not appropriate. Government employees are subject to state and federal laws and ethics rules that may limit your ability to receive any gifts, including meals, from pharmaceutical companies. If you are a state or federal employee, it is your responsibility to seek guidance and prior approval from your employer or site ethics counselor to attend this event.

State Laws: To comply with law and Amgen policies, Amgen is unable to offer food and beverages to (1) individuals with prescribing authority in Vermont or Minnesota; or (2) individuals employed by prescribers in Vermont who support the provision of healthcare. Please confirm the value of the meal with your Amgen representative before accepting the meal. You have the opportunity to opt-out of the meal and/or purchase your own meal, if applicable. Please note that Amgen exercises diligence in reviewing the licensure of attendees and asks that you cooperate by disclosing all licensures in the sign-in/registration process. We appreciate your understanding and support.

Disclosure by Amgen: Amgen reports payments and transfers of value made to healthcare professionals and other healthcare-related entities in accordance with federal and state laws, regulations and other transparency obligations. Any items of value provided by Amgen at this event (including the provision of meals and refreshments) may be subject to public disclosure. If you have questions regarding this matter please contact Amgen at 805-447-7422 or HCCSpendInquiry@amgen.com.

ANCA = anti-neutrophil cytoplasmic autoantibody; CDC = Centers for Disease Control and Prevention; COVID-19 = coronavirus disease 2019; GPA = granulomatosis with polyangiitis; MPA = microscopic polyangiitis; PhRMA = Pharmaceutical Research and Manufacturers of America.

This program is created and sponsored by Amgen. This is not an official program of the American College of Rheumatology.



© 2023-2024 Amgen Inc. All rights reserved.
USA-569-80811 07/24



You're Invited:
Educational Program on Sjögren's Disease

Reframing Sjögren's Disease:
Not a syndrome, but a systemic
autoimmune disease that can be
serious and progressive

Sponsored by Novartis Pharmaceuticals Corporation
Intended for US Health Care Professionals.

January 27, 2026
7:00 PM – 8:00 PM MT

Salon A-B
The Viewline
Snowmass, CO
Meal will be provided.

Sjögren's disease is a systemic, heterogeneous autoimmune disease that can be serious and progressive, with the potential for organ involvement. Discover the systemic manifestations, underlying pathogenesis, daily challenges that impact quality of life, and the potential for a comprehensive management approach.



Presented by

Dana DiRenzo, MD, MHS

Assistant Professor of Clinical Medicine
in the Division of Rheumatology
Penn Medicine
Philadelphia, PA

The speaker is being paid by Novartis Pharmaceuticals Corporation to conduct this presentation.

See how Sjögren's Sjöuts—visit
SjogrensSjoutsHCP.com to learn more!

Novartis Pharmaceuticals Corporation (NPC) may not be able to offer you food or beverages if you are licensed by a state with a meal limit or prohibition, if you are a government employee or member of a formulary committee, or if your institution or affiliation prohibits your acceptance of a meal from a pharmaceutical industry representative. NPC relies on you to ensure mutual compliance with all applicable laws and policies.

Novartis acts in accordance with the PhRMA Code on Interactions With Health Care Professionals. The PhRMA Code states that inclusion of a health care professional's spouse or guest at an educational program is not appropriate. Your support of these ethical guidelines will help ensure a high-quality learning environment for all participating health care professionals. Thank you.

This program is sponsored by Novartis. This is not an official program of the American College of Rheumatology.



**The ACR would like to thank the
WRS26 Planning Committee:**

Silvia Ross, MD—*Chair*
TRIANGLE ARTHRITIS AND RHEUMATOLOGY

John FitzGerald, MD, PhD, RhMSUS
UCLA MEDICAL CENTER

Francesco Boin, MD
CEDARS-SINAI MEDICAL CENTER

Peter Merkel, MD, MPH
UNIVERSITY OF PENNSYLVANIA

AMERICAN COLLEGE
of RHEUMATOLOGY
Empowering Rheumatology Professionals

ACR | Winter Rheumatology
SYMPOSIUM



Thank You to Our Sponsors!


Inmedix
INNOVATIVE MEDICAL DISCOVERY

MAIN SPONSOR

AMGEN[®]

ISS SPONSOR, SUPPORTING SPONSOR

 **NOVARTIS**

ISS SPONSOR

abbvie

SUPPORTING SPONSOR

Be Sure to Visit Our Exhibitors!

abbvie  **AMGEN**[®] **argenx** 

artiva 

AstraZeneca 

 **Boehringer
Ingelheim**

 **Biogen**

 **Bristol Myers Squibb**[™]

GSK

House Rx 


Inmedix
INNOVATIVE MEDICAL DISCOVERY

Johnson & Johnson

Lilly



Mallinckrodt
Pharmaceuticals

 **NOVARTIS**

 **priovent**
therapeutics

sanofi
REGENERON

 **sobi**

